Atuveciclib
Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC50 of 13 nM[1].
Product Specifications
CAS Number
[2923012-24-0]
Product Name Alternative
BAY-1143572
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BAY-1143572.html
Purity
99.75
Solubility
DMSO : ≥ 128.5 mg/mL
Smiles
N=[S@](CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O
Molecular Formula
C18H18FN5O2S
Molecular Weight
387.43
References & Citations
[1]Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12 (21) :1776-1793.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
CDK1; CDK2; CDK3; CDK5; CDK9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7081743 Inquire
Recombinant Chlorobium limicola f.sp. thiosulfatophilum Cytochrome bc complex cytochrome b subunit (petB), partial
Ask
View Details